i

Prognostic Utility of BRAF V600E Mutation as a Risk Factor for Tumor Recurrence Among Filipino Patients with Papillary Thyroid Cancer

PHRR211014-004007

Prognostic Utility of BRAF V600E Mutation as a Risk Factor for Tumor Recurrence Among Filipino Patients with Papillary Thyroid Cancer

Background: Epidemiological studies have showed that Filipinos have a higher prevalence of well-differentiated thyroid cancer as well as higher risk of recurrence. Local practice guidelines have supported more aggressive surgical management followed by radioactive iodine ablation therapy. The BRAF V600E gene mutation has long been proposed as a potential prognostic marker seen in more aggressive forms of papillary thyroid cancer (PTC).

Objectives: We determined whether BRAF V600E mutation can be a novel risk factor for tumor recurrence among Filipino patients with papillary thyroid carcinoma

Methodology: An age and sex-matched case-control study of 14 cases and 14 controls was conducted using our Thyroid Cancer Registry patients with a histopathologic diagnosis of PTC and an available paraffin block as sample source. Pertinent demographic, clinical and histopathologic data were collected. The BRAF V600E mutation was detected using polymerase chain reaction (PCR) amplification after DNA extraction from the paraffin-embedded thyroid tissue blocks. Multivariate conditional logistic regression was undertaken to determine the association of the presence of BRAF V600E with tumor recurrence adjusting for other prognostic factors.

Results: The BRAF V600E mutation prevalence was at 32.14% (95%CI: 15.88% - 52.35%) for all cases; 21.43% (95%CI:4.66%-50.80%) among those with recurrence and 42.86% (95%CI:17.66%-71.14%) among those without recurrence. There was insufficient evidence to prove a significant association between BRAF V600E mutation and PTC recurrence following surgery and RAI, OR 0.50 (95% CI: 0.08 – 2.34, p = 0.327).

Conclusion: Among Filipino patients diagnosed with papillary thyroid cancer, the presence of the BRAF V600E mutation was not associated with increased recurrence rates. However, our study did not meet the required sample size to reach sufficient statistical power due to sample size limitations and sample retrieval. A prospective study with a larger sample size and longer duration of follow-up is needed to firmly establish the role of BRAF V600E in terms of tumor recurrence.

Regime Classification Priority
2017 - 2022
Start Date Duration in Months Target Completion Date Actual Completion Date
2018-01-01 36 2021-01-01 0000-00-00

Completed

Institution Classification Region LTO #
University of the Philippines - Philippine General Hospital Government NCR
Institution Classification Region LTO #
Philippine Society of Endocrinology, Diabetes and Metabolism Private Non-profit Philippines
Institution Region
Philippine Society of Endocrinology, Diabetes and Metabolism Philippines
Name E-Mail Institution and Institution Address
Harold Henrison Chang Chiu hcchiu@up.edu.ph Taft Avenue, Ermita
Name E-Mail Institution and Institution Address
Harold Henrison Chang Chiu hcchiu@up.edu.ph Taft Avenue, Ermita
Name Expertise Affiliation
Anna Angelica Macalalad-Josue, MD Endocrinology University of the Philippines - Philippine General Hospital
Patricia Maningat, MD Endocrinology University of the Philippines - Philippine General Hospital

In this study, we determined the association of BRAF V600E mutations with tumor recurrence in papillary thyroid cancer among Filipinos. Specifically, we determined the prevalence of BRAFV600E mutation in histopathologic samples of papillary thyroid cancer; we investigated BRAF V600E as a potential risk factor for tumor recurrence; and lastly, we determined the association of BRAFV600E mutations with clinical parameters, tumor characteristics, presence of lymph node metastasis and stage of disease.

 

BRAF V600E mutation in patients with papillary thyroid cancer with or without recurrence

Unspecified

Completed

  • Philippines

Non-clinical Studies

©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date